ATTR

Eidos Therapeutics

This biopharmaceutical company develops acoramidis, a small molecule therapy designed to treat patients suffering from transthyretin amyloidosis by stabilising the transthyretin protein.

Protego

This clinical-stage biotechnology company develops small molecule therapies that stabilise proteins to treat amyloidosis and other protein misfolding diseases for patients with organ damage.

AMYL THERAPEUTICS

The company develops pan-amyloid immunotherapies to treat patients with neurodegenerative and rare diseases caused by toxic protein aggregates.

Immutrin

This biotechnology company develops antibody therapies to remove amyloid deposits and treat cardiomyopathy for patients with amyloidosis.

Protego Biopharma

This biotechnology company develops small molecule therapies for patients with systemic amyloid diseases and other protein misfolding disorders.

Brano Therapeutics

This company develops small-molecule inhibitors to treat heart failure and metabolic dysfunction for patients with cardiovascular diseases.

Attenua

This company develops small-molecule medicines for patients suffering from chronic respiratory disorders, particularly chronic cough.

Ambagon Therapeutics

The company develops small-molecule stabilisers to modulate protein interactions for the treatment of cancer and other serious diseases.